Cargando…

Using macrophage activation to augment immunotherapy of established tumours

BACKGROUND: Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fridlender, Z G, Jassar, A, Mishalian, I, Wang, L-CS, Kapoor, V, Cheng, G, Sun, J, Singhal, S, Levy, L, Albelda, S M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619255/ https://www.ncbi.nlm.nih.gov/pubmed/23481183 http://dx.doi.org/10.1038/bjc.2013.93

Ejemplares similares

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
por: Šímová, J, et al.
Publicado: (2011)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice
por: Gil, M, et al.
Publicado: (2011)

Modifying tumor-associated macrophages: An important adjunct to immunotherapy
por: Fridlender, Zvi G, et al.
Publicado: (2013)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

Transcriptomic Analysis Comparing Tumor-Associated Neutrophils with Granulocytic Myeloid-Derived Suppressor Cells and Normal Neutrophils
por: Fridlender, Zvi G., et al.
Publicado: (2012)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
por: Zeisberger, S M, et al.
Publicado: (2006)

WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages
por: Lee, Geun Taek, et al.
Publicado: (2018)

Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
por: Hardee, M E, et al.
Publicado: (2005)

Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy
por: Dudek, A Z, et al.
Publicado: (2007)

The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens
por: Steele, J C, et al.
Publicado: (2006)

A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma
por: Sun, Wei, et al.
Publicado: (2017)

Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo
por: Oikonomou, E, et al.
Publicado: (2007)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy
por: Golding, J P, et al.
Publicado: (2013)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation
por: Hennig, R, et al.
Publicado: (2008)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
por: Quintela-Fandino, M, et al.
Publicado: (2013)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
por: Damiano, V, et al.
Publicado: (2013)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy
por: Pirovano, Giacomo, et al.
Publicado: (2017)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery
por: Wang, Y, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_l4fjqcnru6iikrp3ekm7svajjj